GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » Cyclically Adjusted FCF per Share

MTNB (Matinas BioPharma Holdings) Cyclically Adjusted FCF per Share : $-6.49 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Matinas BioPharma Holdings's adjusted free cash flow per share for the three months ended in Sep. 2024 was $-0.695. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-6.49 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-04-13), Matinas BioPharma Holdings's current stock price is $0.54. Matinas BioPharma Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $-6.49. Matinas BioPharma Holdings's Cyclically Adjusted Price-to-FCF of today is .


Matinas BioPharma Holdings Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Matinas BioPharma Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Cyclically Adjusted FCF per Share Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -7.25 -7.23

Matinas BioPharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.50 -7.23 -7.03 -6.74 -6.49

Competitive Comparison of Matinas BioPharma Holdings's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Matinas BioPharma Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Cyclically Adjusted Price-to-FCF falls into.


;
;

Matinas BioPharma Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Matinas BioPharma Holdings's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.695/133.0289*133.0289
=-0.695

Current CPI (Sep. 2024) = 133.0289.

Matinas BioPharma Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -3.746 99.070 -5.030
201503 -3.274 99.621 -4.372
201506 -2.012 100.684 -2.658
201509 -1.908 100.392 -2.528
201512 -0.997 99.792 -1.329
201603 -1.346 100.470 -1.782
201606 -0.950 101.688 -1.243
201609 -1.185 101.861 -1.548
201612 -1.821 101.863 -2.378
201703 -1.792 102.862 -2.318
201706 -2.035 103.349 -2.619
201709 -1.510 104.136 -1.929
201712 -1.024 104.011 -1.310
201803 -1.554 105.290 -1.963
201806 -1.285 106.317 -1.608
201809 -1.538 106.507 -1.921
201812 -1.189 105.998 -1.492
201903 -1.294 107.251 -1.605
201906 -0.844 108.070 -1.039
201909 -1.321 108.329 -1.622
201912 -1.503 108.420 -1.844
202003 -1.219 108.902 -1.489
202006 -0.802 108.767 -0.981
202009 -1.314 109.815 -1.592
202012 -1.081 109.897 -1.309
202103 -1.141 111.754 -1.358
202106 -0.211 114.631 -0.245
202109 -1.336 115.734 -1.536
202112 -0.915 117.630 -1.035
202203 -1.223 121.301 -1.341
202206 -1.196 125.017 -1.273
202209 -1.204 125.227 -1.279
202212 -1.001 125.222 -1.063
202303 -0.941 127.348 -0.983
202306 -0.505 128.729 -0.522
202309 -1.017 129.860 -1.042
202312 -1.054 129.419 -1.083
202403 -1.327 131.776 -1.340
202406 -0.623 132.554 -0.625
202409 -0.695 133.029 -0.695

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Matinas BioPharma Holdings  (AMEX:MTNB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Matinas BioPharma Holdings Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings Business Description

Traded in Other Exchanges
N/A
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Executives
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Roelof Rongen director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921